FTSE 100 drops nearly 20 points as major firms go ex-dividend, led by HSBC and BP.

Spero Therapeutics reports Q1 2026 loss narrows; FDA to decide on oral antibiotic tebipenem HBr in June

Spero Therapeutics announced its financial results for Q1 2026, reporting a net loss of $7.2 million, an improvement from $13.9 million loss in Q1 2025, driven by reduced R&D and administrative expenses. The company is awaiting an FDA decision on its...